Fang W, Yu Z, Chen C, Chen G, Chen K, Fu J
Mediastinum. 2024; 8:27.
PMID: 38881812
PMC: 11176998.
DOI: 10.21037/med-23-54.
Hojo N, Nagasaki M, Mihara Y
World J Clin Cases. 2022; 10(17):5708-5716.
PMID: 35979119
PMC: 9258378.
DOI: 10.12998/wjcc.v10.i17.5708.
Yu Y, Dong X, Tu M, Wang H
Thorac Cancer. 2021; 12(21):2831-2837.
PMID: 34590432
PMC: 8563158.
DOI: 10.1111/1759-7714.14155.
Svoboda J, Bair S, Landsburg D, Nasta S, Nagle S, Barta S
Haematologica. 2020; 106(6):1705-1713.
PMID: 32414850
PMC: 8168499.
DOI: 10.3324/haematol.2019.238675.
Hashimoto Y, Omura H, Tokuyasu Y, Nakamoto S, Tanaka T
Intern Med. 2019; 58(23):3455-3459.
PMID: 31391392
PMC: 6928502.
DOI: 10.2169/internalmedicine.3129-19.
The Unsolved Puzzle of c-Rel in B Cell Lymphoma.
Kober-Hasslacher M, Schmidt-Supprian M
Cancers (Basel). 2019; 11(7).
PMID: 31277480
PMC: 6678315.
DOI: 10.3390/cancers11070941.
Distribution of malignant lymphomas in the anterior mediastinum: a single-institution study of 76 cases in Japan, 1997-2016.
Maeshima A, Taniguchi H, Suzuki T, Yuda S, Toyoda K, Yamauchi N
Int J Hematol. 2017; 106(5):675-680.
PMID: 28921451
DOI: 10.1007/s12185-017-2331-0.
Primary Mediastinal Large B-cell Lymphoma Exhibiting Endobronchial Involvement.
Shimada M, Fukuda M, Horio K, Suyama T, Kitazaki T, Hashiguchi K
Intern Med. 2016; 55(21):3147-3150.
PMID: 27803409
PMC: 5140864.
DOI: 10.2169/internalmedicine.55.7117.
Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.
Lennerz J, Hoffmann K, Bubolz A, Lessel D, Welke C, Ruther N
Oncotarget. 2015; 6(30):29097-110.
PMID: 26336985
PMC: 4745714.
DOI: 10.18632/oncotarget.4829.
The histological classification of diffuse large B-cell lymphomas.
Xie Y, Pittaluga S, Jaffe E
Semin Hematol. 2015; 52(2):57-66.
PMID: 25805585
PMC: 4374126.
DOI: 10.1053/j.seminhematol.2015.01.006.
EBV-Positive Grey Zone Lymphoma in an HIV Infected Man from Kampala, Uganda: Case Report.
Tumwine L, Orem J, Ayers L
Int J Med Pharm Case Reports. 2015; 2(5):110-116.
PMID: 25599090
PMC: 4293704.
DOI: 10.9734/IJMPCR/2015/13625.
Double-punching PMBL.
Lennerz J
Oncotarget. 2014; 5(22):10965-6.
PMID: 25473898
PMC: 4294352.
DOI: 10.18632/oncotarget.2827.
The truncate mutation of Notch2 enhances cell proliferation through activating the NF-κB signal pathway in the diffuse large B-cell lymphomas.
Zhang X, Shi Y, Weng Y, Lai Q, Luo T, Zhao J
PLoS One. 2014; 9(10):e108747.
PMID: 25314575
PMC: 4196756.
DOI: 10.1371/journal.pone.0108747.
Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan.
Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K
Haematologica. 2014; 99(12):1817-25.
PMID: 25216682
PMC: 4258760.
DOI: 10.3324/haematol.2014.111203.
KIT mutations in primary mediastinal B-cell lymphoma.
Nagel P, Stenzinger A, Feld F, Herrmann M, Bruderlein S, Barth T
Blood Cancer J. 2014; 4:e241.
PMID: 25148223
PMC: 4219474.
DOI: 10.1038/bcj.2014.61.
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.
Shi M, Roemer M, Chapuy B, Liao X, Sun H, Pinkus G
Am J Surg Pathol. 2014; 38(12):1715-23.
PMID: 25025450
PMC: 4994970.
DOI: 10.1097/PAS.0000000000000297.
Thymic neoplasm: a rare disease with a complex clinical presentation.
Rashid O, Cassano A, Takabe K
J Thorac Dis. 2013; 5(2):173-83.
PMID: 23585946
PMC: 3621939.
DOI: 10.3978/j.issn.2072-1439.2013.01.12.
[Lymph node pathology - an update].
Hartmann S, Hansmann M
Pathologe. 2013; 34(1):34-44.
PMID: 23319007
DOI: 10.1007/s00292-012-1706-5.
SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.
Schif B, Lennerz J, Kohler C, Bentink S, Kreuz M, Melzner I
Oncotarget. 2013; 4(1):35-47.
PMID: 23296022
PMC: 3702206.
DOI: 10.18632/oncotarget.774.
Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions.
Karanikas M, Machairiotis N, Zarogoulidis P, Stylianaki A, Corcoutsakis N, Mitrakas A
Onco Targets Ther. 2012; 5:433-8.
PMID: 23251094
PMC: 3525048.
DOI: 10.2147/OTT.S38645.